Skip to main content
Contact Us
Subscribe
E-Edition
92°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
107.78
-0.74 (-0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
Earnings Preview For Blueprint Medicines
February 15, 2023
Via
Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
February 10, 2023
Via
Benzinga
Analyst Ratings for Blueprint Medicines
January 23, 2023
Via
Benzinga
Blueprint Medicines's Return On Capital Employed Overview
November 07, 2022
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16...
Via
Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
November 02, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
November 02, 2022
Upgrades
Via
Benzinga
9 Analysts Have This to Say About Blueprint Medicines
November 02, 2022
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
December 12, 2022
Via
Benzinga
Recap: Blueprint Medicines Q3 Earnings
November 01, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
November 02, 2022
Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
September 09, 2022
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter:
Via
Benzinga
Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says
August 18, 2022
Via
Benzinga
Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data
August 17, 2022
Via
Benzinga
What 14 Analyst Ratings Have To Say About Blueprint Medicines
August 22, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
August 22, 2022
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.
Via
Benzinga
Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares
August 17, 2022
Blueprint Medicines Corporation (NASDAQ: BPMC)
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
August 03, 2022
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Via
Benzinga
Blueprint Medicines: Q2 Earnings Insights
August 02, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
August 18, 2022
Gainers
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 17, 2022
Via
Benzinga
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
August 17, 2022
Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.
Via
Benzinga
U.S. Stocks Open Lower; Nasdaq Down 150 Points
August 17, 2022
U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday.
Via
Benzinga
Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening?
August 17, 2022
Blueprint Medicines Corp (NASDAQ: BPMC) shares are trading lower by 22.2% to $53.32 Wednesday morning after the company announced top-line results from the registrational Part 2 of the PIONEER clinical...
Via
Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
August 17, 2022
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus...
Via
Benzinga
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
August 17, 2022
Blueprint Medicines met all its goals, but the results paled from an earlier study.
Via
Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
August 17, 2022
Blueprint Medicines (NASDAQ: BPMC) announced positive top-line results from the Part 2 of PIONEER clinical trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis (SM).
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 17, 2022
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.